Skip to main content

Symyx Board Rejects 'Final' Certara Offer

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Symyx Technologies today said that its board of directors has rejected Certara's "best and final" offer to acquire Symyx for $5.75 per share in cash, or around $200 million.

It is the third time in the past two weeks that Symyx has declined Certara's bid, saying it does not constitute a superior offer to Accelrys' offer to buy the firm for $5 per share. Symyx has repeatedly said that the deal with Accelrys offers a greater upside and has urged its shareholders to back the merger with Accelrys.

Symyx said that it expects to close the deal with Accelrys, under which shareholders of each firm own around 50 percent of the combined company, at the beginning of July.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.